The objective of the Scheme is to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies.
Expert-managed portfolios tailored to your financial goals and risk appetite.
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -8.31% | -1.37% | 13.78% | 16.39% | 10.63% | N/A | N/A | N/A | N/A | N/A | 4.94% |
| Category returns | -7.54% | -3.42% | 10.54% | 13.4% | 8.01% | 3.9% | 18.22% | 18.48% | 12.78% | 13.01% | N/A |
| Absolute returns | -8.31% | -1.37% | 13.78% | 16.39% | 10.63% | N/A | N/A | N/A | N/A | N/A | 9.13% |
| Rank within category | 17/19 | 2/18 | 2/18 | 7/18 | 6/17 | N/A | N/A | N/A | N/A | N/A | N/A |
| Sector Funds | 2024 | 2025 | 2026 |
|---|---|---|---|
| Yearly returns | N/A | -4.58% | 13.26% |
| Q1 returns | N/A | -10.08% | -5.84% |
| Q2 returns | N/A | 6.76% | 19.69% |
| Q3 returns | N/A | -2.45% | 5.47% |
| Q4 returns | N/A | 1.89% | -4.71% |
1% on or before 3M, Nil after 3M
| Alpha | 0.679023 |
| Beta | 0.6294 |
| Sharpe Ratio | 0.0951172 |
| Sortino Ratio | 0.176221 |
| R-Squared | 0.2767 |
| Tracking Error | 3.8417 |
| Downside Risk | 16.4965 |
| Std. Deviation (Annualised) | 14.7109 |
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Exp. Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDFC Pharma and Healthcare Fund - Regular Plan - Growth | -8.18% | -2.85% | 13.49% | 19.65% | 16.65% | 26.3% | N/A | N/A | 26.16% | 3,501.37 | 2.11 | 0.45 | Very High |
| SBI Healthcare Opportunities Fund - Regular Plan - IDCW | -7.91% | -3.95% | 12% | 16.9% | 9.98% | 20.31% | 16% | 12.88% | 16.36% | 5,870.00 | 1.99 | 0.33 | Very High |
| UTI Healthcare Fund - Regular Plan - IDCW | -8.04% | -4.49% | 10.8% | 14.7% | 7.94% | 19.65% | 13.41% | 12.86% | 14.71% | 1,429.84 | 2.22 | 0.32 | Very High |
| Mirae Asset Healthcare Fund - Regular Plan - Growth | -6.65% | -2.37% | 10.95% | 15.8% | 10.86% | 19.1% | 13.11% | N/A | 19.31% | 3,494.44 | 2.04 | 0.30 | Very High |
| ICICI Prudential Healthcare Fund - Growth | -5.27% | -5.77% | 5.31% | 6.11% | 1.04% | 18.9% | 14.21% | N/A | 18.53% | 6,861.20 | 2.08 | 0.30 | Very High |
| LIC MF Healthcare Fund - Regular Plan - Growth | -8.31% | -3.16% | 10.44% | 10.22% | 4.45% | 18.2% | 9.97% | N/A | 16.14% | 99.36 | 2.67 | 0.28 | Very High |
| DSP Healthcare Fund - Regular Plan - Growth | -5.87% | -2.13% | 13.11% | 11.93% | 9.74% | 17.47% | 13.29% | N/A | 20.34% | 3,750.04 | 2.05 | 0.29 | Very High |
| Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth | -7.92% | -5.04% | 8.82% | 11.15% | 7.84% | 16.89% | 11.54% | N/A | 18.16% | 1,077.52 | 2.29 | 0.27 | Very High |
| Quant Healthcare Fund - Regular Plan - Growth | -7.41% | -1.49% | 10.61% | 18.21% | 9.71% | 16.57% | N/A | N/A | 17.69% | 424.53 | 3.13 | 0.23 | Very High |
| Bajaj Finserv Healthcare Fund - Regular Plan - Growth Current | -8.31% | -1.37% | 13.78% | 16.39% | 10.63% | N/A | N/A | N/A | 4.94% | 405.14 | 2.59 | 0.10 | Very High |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 9.75% |
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 8.96% |
| Piramal Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.36% |
| Rubicon Research Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.08% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.03% |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Domestic Equities | 5.51% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.78% |
| Emcure Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.03% |
| Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.91% |
| Neuland Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.82% |
| Max Healthcare Institute Ltd. | Healthcare Services | Domestic Equities | 2.99% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.96% |
| Zydus Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.57% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.40% |
| Clearing Corporation of India Ltd | Cash & Cash Equivalents and Net Assets | 2.32% | |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 2.28% |
| Zydus Wellness Ltd. | Food Products | Domestic Equities | 2.20% |
| Vijaya Diagnostic Centre Ltd. | Healthcare Services | Domestic Equities | 2.19% |
| Senores Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.08% |
| Shaily Engineering Plastics Ltd. | Consumer Durables | Domestic Equities | 1.88% |
| Dr. Lal Pathlabs Ltd. | Healthcare Services | Domestic Equities | 1.73% |
| Glaxosmithkline Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.63% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.60% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.37% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.33% |
| Bajaj Finserv Money Market Fund-Direct Plan-Growth | Domestic Mutual Funds Units | 1.31% | |
| Sanofi Consumer Healthcare India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.30% |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.05% |
| Navin Fluorine International Ltd. | Chemicals & Petrochemicals | Domestic Equities | 0.94% |
| Krishna Institute of Medical Sciences Ltd | Healthcare Services | Domestic Equities | 0.92% |
| Jubilant Pharmova Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.89% |
| Onesource Specialty Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.83% |
| Net Receivables / (Payables) | Cash & Cash Equivalents and Net Assets | 0.82% | |
| Medi Assist Healthcare Services Ltd. | Insurance | Domestic Equities | 0.75% |
| Neogen Chemicals Ltd. | Chemicals & Petrochemicals | Domestic Equities | 0.23% |
| Sumitomo Chemical India Ltd. | Fertilizers & Agrochemicals | Domestic Equities | 0.21% |
| Total | 100.00% | ||
Mr. Siddharth is a B Com and PG Diploma in Securities Markets from the Indian Institute of Capital Markets. He is also a Level II CFA.He jointly manages Sundaram Money Fund, Sundaram Ultra Short-Term Fund, Sundaram Flexible Fund Short-Term Plan, Sundaram Capital Protection Oriented Funds, Sundaram Monthly Income Plan and Sundaram Fixed Income Interval Funds along with Dwijendra Srivastava.His previous experience includes 4 years in Indian Bank as Fixed Income and Derivatives Dealer.
Mr. Vinay Bafna has been associated with the AMC as Research Analyst. Prior to joining the AMC, he was associated with ICICI Securities Limited as a Research Analyst, tracking metals & commodities, pharma. He has over 10 years of work experience in researching different commodities market and sectors such as metals & commodities, pharma, IT, hospitality and supporting ERP used by global commodity clients.
Mr. Bharat Hegde joined the Company in July 2024 as a Senior Research Analyst - Megatrends and has been actively engaged in tracking and identifying domestic and global megatrends. In addition, he is engaged in ideation, and in-depth company and sector research for equity funds on multiple sectors such as IT, Defence, Power, Capital goodsand electric Utilities. Prior to joining the Company, he was associated with Bharti AXA LifeInsurance Co Ltd, MotilalOswal Financial Services Ltd, SBICAP Securities Ltd, and CRISIL Global Research & Analytics.
Get personalized portfolio management services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
